医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Visioneering Technologies Inc. Appoints Dr. Peg Achenbach as Vice President, Professional Services and Clinical Science

2018年11月29日 PM09:22
このエントリーをはてなブックマークに追加


 

ATLANTA

To ensure that Eye Care Professionals (ECPs) fully connect with its technology and growing product portfolio, Visioneering Technologies Inc. (VTI), a global company dedicated to improving vision care, has named Peg Achenbach, OD, FAAO as Vice President, Professional Services and Clinical Science.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181129005107/en/

Peg Achenbach, OD, FAAO has been named Vice President for Professional Services and Clinical Science ...

Peg Achenbach, OD, FAAO has been named Vice President for Professional Services and Clinical Science by Visioneering Technologies, Inc. (Photo: Business Wire)

In her new position, Dr. Achenbach will be responsible for increasing awareness of VTI’s portfolio of products and developing programs that help VTI better support independent ECPs to help them improve their businesses and clinical practices. She will also be working with leading ECPs in the U.S. and globally to expand participation in research studies and leading efforts to publish findings in key journals.

“Dr. Achenbach’s impressive resume and career history highlight our goal to seek out leaders in our industry to help us tell our story and better engage ECPs,” said Visioneering’s CEO, Stephen Snowdy, PhD. “We are pleased to have her join our team and look forward to the many contributions she will make to our organization as we seek to broaden our profile nationally and internationally.”

Achenbach’s professional career includes 16 years of private practice specializing in contact lenses and low vision. Additionally, she has been involved in research and drug development in oncology, HIV, dermatology and nutritional supplements as a co-founder of a biotech company. She is a member of the Association for Research in Vision and Ophthalmology (ARVO), the British Contact Lens Association (BCLA), International Association of Contact Lens Educators (IACLE), the American Optometric Association (AOA) and is a Fellow of the American Academy of Optometry (FAAO). She obtained her undergraduate degree in Aeronautics from the University of North Dakota and her degree in Optometry from Pacific University College of Optometry.

“After nearly two decades in this industry, the innovations developed continue to amaze me,” said Achenbach. “VTI is an example of the kind of organization dedicated to bringing products to the global marketplace to improve vision for patients of all ages. I look forward to working with my peers to help them better understand the exciting and promising products offered by VTI.”

To contact Dr. Achenbach directly, email PAchenbach@vtivision.com.

About Visioneering Technologies, Inc.

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI’s Neurofocus Optics® technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and received the CE Mark, as well as TGA approval in early 2018. VTI recently commenced its US market expansion for NaturalVue MF contact lenses, and has broadened its reach into international markets in 2018. VTI also sells and plans additional contact lens products.

For more information, visit www.vtivision.com or call 844-884-5367.

MKT-VTI-PR68

Disclaimer: This information describes uses for multifocal contact lenses that have not been approved or cleared by the FDA for use in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181129005107/en/

CONTACT

Layna L. Mendlinger
info@vtivision.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • AMRA、身体組成の非侵襲的測定を実現する磁気共鳴診断ソフトウエアアプリケーションのAMRA® Profilerで米国FDAの承認を取得
  • AMRA用于机体成分无创评估的磁共振诊断软件AMRA® Profiler获得美国FDA核准
  • Haidian District People’s Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Beijing
  • CDISC and Cohen Veterans Bioscience Announce Release of First Data Standard to Improve Research for Post Traumatic Stress Disorder
  • 武田薬品とニューヨーク科学アカデミーによる”2019 Innovators in Science Award”の受賞者発表について